All posts by: Michael Zand

About Michael Zand

Here’s Why Amyris Stock Jumped as Much as 28.5% Higher Today – Madison.com

Continue reading

2018-03-16 NEWS

Madison.com

Here’s Why Amyris Stock Jumped as Much as 28.5% Higher Today
Madison.com
Shares of synthetic biology pioneer Amyris (NASDAQ: AMRS) soared over 28% today after the company announced fourth-quarter and full-year 2017 earnings. The company reported 113% revenue growth in 2017 compared to 2016, guided for up to $195 million in
Noteworthy Stocks to Watch for: Amyris, Inc. (NASDAQ:AMRS), Guess’, Inc. (NYSE:GES)The Oracle Examiner
Amyris (AMRS) Upgraded at Zacks Investment Researchregistrarjournal.com

all 13 news articles »

Continue reading

2018-03-16 NEWS

Madison.com

Here’s Why Amyris Stock Jumped as Much as 28.5% Higher Today
Madison.com
Shares of synthetic biology pioneer Amyris (NASDAQ: AMRS) soared over 28% today after the company announced fourth-quarter and full-year 2017 earnings. The company reported 113% revenue growth in 2017 compared to 2016, guided for up to $195 million in
Noteworthy Stocks to Watch for: Amyris, Inc. (NASDAQ:AMRS), Guess’, Inc. (NYSE:GES)The Oracle Examiner
Amyris (AMRS) Upgraded at Zacks Investment Researchregistrarjournal.com

all 13 news articles »

Continue reading

2018-03-16 NEWS

Nasdaq

Here’s an ETF to Invest in Immunotherapy–the Game Changing Cancer Treatment
Nasdaq
In this episode of ETF Spotlight, I talked with Brad Loncar, CEO of Loncar Investments, who created the Loncar Cancer Immunotherapy Index, the underlying benchmark for the Loncar Cancer Immunotherapy ETF CNCR . Immunotherapy is often called a game

Continue reading

2018-03-16 NEWS

registrarjournal.com

Here’s Why Amyris Stock Jumped as Much as 28.5% Higher Today
Fox Business
Shares of synthetic biology pioneer Amyris (NASDAQ: AMRS) soared over 28% today after the company announced fourth-quarter and full-year 2017 earnings. The company reported 113% revenue growth in 2017 compared to 2016, guided for up to $195 million in
Noteworthy Stocks to Watch for: Amyris, Inc. (NASDAQ:AMRS), Guess’, Inc. (NYSE:GES)The Oracle Examiner
Amyris (AMRS) Upgraded at Zacks Investment Researchregistrarjournal.com
The Amyris (AMRS) Posts Earnings Results, Beats Expectations By $0.54 EPSBangaloreWeekly

all 7 news articles »

Continue reading

2018-03-16 NEWS

Digital Trends

In new breakthrough, CRISPR tools target RNA to tackle dementia
Digital Trends
Now a team of researchers from the Salk Institute have identified a new family of CRISPR enzymes that target RNA instead of DNA, and used the tool to address protein imbalance in cells isolated from a person suffering from dementia. “RNA ‘messages’ are

and more »